AI Portfolio Summary
In 2025 Q4, Commodore Capital LP maintained a portfolio of 43 distinct positions. The most significant new addition to the portfolio was ALTO NEUROSCIENCE IN, which now represents 2.16% of the total fund value. They heavily accumulated shares in ALKERMES PLC, increasing their position by 14.6%. Conversely, Commodore Capital LP completely exited their position in CRESCENT BIOPHARMA I.
Total Positions
43
Quarter
2025 Q4
Top Holding
RLAY (9.6%)
Top 10 Concentration
55.8%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-43 of 43
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
RLAY
RELAY THERAPEUT...
|
Healthcare | 9.57% | 4.33% |
#1
8
Prev: #9
|
6.8 | no change | no change |
P
S
|
17,000,000 | $143,820,000 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 6.61% | 4.54% |
#2
5
Prev: #7
|
6.1 | 453,246 | 14.6% |
P
S
|
3,550,000 | $99,329,000 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TYRA
TYRA BIOSCIENCE...
|
Healthcare | 5.91% | 2.30% |
#3
14
Prev: #17
|
4.4 | no change | no change |
P
S
|
3,375,000 | $88,728,750 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 5.37% | 5.29% |
#4
1
Prev: #3
|
2.6 | -900,000 | -33.3% |
P
S
|
1,800,000 | $80,676,000 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 5.21% | 1.63% |
#5
18
Prev: #23
|
5.1 | 400,161 | 20.1% |
P
S
|
2,388,245 | $78,238,906 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
COGT
COGENT BIOSCIEN...
|
Healthcare | 5.19% | 5.08% |
#6
2
Prev: #4
|
2.1 | -5,053,155 | -69.7% |
P
S
|
2,196,845 | $78,031,934 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 4.81% | 4.69% |
#7
2
Prev: #5
|
2.9 | no change | no change |
P
S
|
4,692,809 | $72,269,259 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 4.64% | 3.82% |
#8
2
Prev: #10
|
2.4 | -463,335 | -15.3% |
P
S
|
2,565,000 | $69,665,400 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 4.54% | 2.70% |
#9
7
Prev: #16
|
4.3 | 1,574,522 | 38.6% |
P
S
|
5,650,000 | $68,252,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 3.97% | 2.09% |
#10
8
Prev: #18
|
1.6 | -4,225,000 | -74.1% |
P
S
|
1,475,000 | $59,590,000 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 3.88% | 2.07% |
#11
8
Prev: #19
|
2.6 | no change | no change |
P
S
|
750,000 | $58,357,500 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 3.70% | 4.46% |
#12
4
Prev: #8
|
2.0 | -150,000 | -11.1% |
P
S
|
1,200,000 | $55,560,000 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NUVL
NUVALENT INC
|
Healthcare | 3.68% | 5.91% |
#13
11
Prev: #2
|
1.5 | -850,000 | -60.7% |
P
S
|
550,000 | $55,324,500 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 3.54% | 1.65% |
#14
8
Prev: #22
|
2.4 | no change | no change |
P
S
|
1,753,054 | $53,135,067 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PHVS
PHARVARIS N V
|
Healthcare | 3.49% | 2.95% |
#15
1
Prev: #14
|
1.4 | -529,031 | -21.9% |
P
S
|
1,889,445 | $52,432,099 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NRIX
NURIX THERAPEUT...
|
Healthcare | 2.87% | 1.71% |
#16
5
Prev: #21
|
1.1 | -1,505,055 | -39.8% |
P
S
|
2,275,000 | $43,156,750 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 2.62% | 3.32% |
#17
4
Prev: #13
|
1.0 | -575,000 | -56.1% |
P
S
|
450,000 | $39,303,000 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASMB
ASSEMBLY BIOSCI...
|
Healthcare | 2.26% | 1.25% |
#18
7
Prev: #25
|
1.9 | no change | no change |
P
S
|
1,000,000 | $34,010,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LBRX
LB PHARMACEUTIC...
|
Healthcare | 2.22% | 1.16% |
#19
8
Prev: #27
|
1.9 | no change | no change |
P
S
|
1,500,000 | $33,390,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CTMX
CYTOMX THERAPEU...
|
Healthcare | 2.18% | 1.20% |
#20
6
Prev: #26
|
1.9 | no change | no change |
P
S
|
7,692,300 | $32,769,198 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ANRO
ALTO NEUROSCIEN...
|
Healthcare | 2.16% | — |
#21
Prev: #—
|
4.4 | 1,823,196 | no change |
NEW
|
1,823,196 | $32,452,889 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PALI
PALISADE BIO IN...
|
Healthcare | 1.79% | — |
#22
Prev: #—
|
4.2 | 11,445,000 | no change |
NEW
|
11,445,000 | $26,895,750 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNMD
MIND MEDICINE M...
|
Healthcare | 1.78% | 1.86% |
#23
3
Prev: #20
|
0.7 | -1,225,000 | -38.0% |
P
S
|
2,000,000 | $26,780,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 1.66% | 3.37% |
#24
13
Prev: #11
|
0.7 | -1,850,000 | -64.9% |
P
S
|
1,000,000 | $25,010,000 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PEPG
PEPGEN INC
|
Healthcare | 1.47% | 0.53% |
#25
5
Prev: #30
|
3.1 | 1,042,681 | 44.2% |
P
S
|
3,400,000 | $22,134,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SABS
SAB BIOTHERAPEU...
|
Healthcare | 1.10% | 0.43% |
#26
6
Prev: #32
|
1.4 | no change | no change |
P
S
|
4,401,500 | $16,461,610 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
REPL
REPLIMUNE GROUP...
|
Healthcare | 0.92% | — |
#27
Prev: #—
|
3.9 | 1,425,000 | no change |
NEW
|
1,425,000 | $13,851,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 0.74% | 0.43% |
#28
5
Prev: #33
|
1.3 | no change | no change |
P
S
|
5,397,488 | $11,064,850 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CTNM
CONTINEUM THERA...
|
Healthcare | 0.62% | — |
#29
Prev: #—
|
3.7 | 816,326 | no change |
NEW
|
816,326 | $9,330,606 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 0.58% | 0.30% |
#30
5
Prev: #35
|
1.2 | no change | no change |
P
S
|
483,000 | $8,771,280 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RAPT
RAPT THERAPEUTI...
|
Healthcare | 0.56% | — |
#31
Prev: #—
|
3.7 | 250,000 | no change |
NEW
|
250,000 | $8,467,500 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LONA
ATHIRA PHARMA I...
|
Healthcare | 0.23% | — |
#32
Prev: #—
|
3.6 | 464,398 | no change |
NEW
|
464,398 | $3,515,493 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DRUG
BRIGHT MINDS BI...
|
Healthcare | 0.10% | 1.48% |
#33
9
Prev: #24
|
0.0 | -481,149 | -96.2% |
P
S
|
18,851 | $1,471,132 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
CRESCENT BIOPHA...
|
—
|
Unknown | 0.00% | 0.26% |
Sold All 😨
(Was: #37) |
0.0 | -450,829 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
VTGN
VISTAGEN THERAP...
|
Healthcare | 0.00% | 0.27% |
Sold All 😨
(Was: #36) |
0.0 | -1,575,000 | -100.0% |
CLOSED
|
— | $— | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCSC
PERCEPTIVE CAP ...
|
Financial Services | 0.00% | 0.39% |
Sold All 😨
(Was: #34) |
0.0 | -750,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENTA
ENANTA PHARMACE...
|
Healthcare | 0.00% | 0.47% |
Sold All 😨
(Was: #31) |
0.0 | -800,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 0.00% | 0.56% |
Sold All 😨
(Was: #29) |
0.0 | -290,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TNGX
TANGO THERAPEUT...
|
Healthcare | 0.00% | 0.62% |
Sold All 😨
(Was: #28) |
0.0 | -1,500,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CDTX
CIDARA THERAPEU...
|
Healthcare | 0.00% | 2.73% |
Sold All 😨
(Was: #15) |
0.0 | -585,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 0.00% | 3.37% |
Sold All 😨
(Was: #12) |
0.0 | -3,200,000 | -100.0% |
CLOSED
|
— | $— | 2021 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AGIO
AGIOS PHARMACEU...
|
Healthcare | 0.00% | 4.58% |
Sold All 😨
(Was: #6) |
0.0 | -2,338,287 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRUS
MERUS N V
|
Healthcare | 0.00% | 16.20% |
Sold All 😨
(Was: #1) |
0.0 | -3,525,000 | -100.0% |
CLOSED
|
— | $— | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-43 of 43 holdings